Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
The vaccine, which contains the R21 antigen specific to the malaria parasite, uses a saponin-based adjuvant called Matrix-M. Developed by biotech firm Novavax, the adjuvant boosts the body’s immune response, and lengthens the period of the vaccine’s effectiveness.
The vaccine, which contains the R21 antigen specific to the malaria parasite, uses a saponin-based adjuvant called Matrix-M. Developed by biotech firm Novavax, the adjuvant boosts the body’s immune response, and lengthens the period of the vaccine’s effectiveness.